Life Science Today

Originally Published as The Niche Podcast

Bristol Myers strikes a $13 billion deal, presidential experiments, the NIH funds under-represented testing, and Sophia Genetics raises $110 million.



Sponsors

https://www.thescopemethod.com

Story References

https://www.businesswire.com/news/home/20201005005381/en/Bristol-Myers-Squibb-to-Acquire-MyoKardia-for-13.1-Billion-in-Cash
https://www.sciencemag.org/news/2020/10/heres-what-known-about-president-donald-trump-s-covid-19-treatment
https://www.nih.gov/news-events/news-releases/nih-assess-expand-covid-19-testing-underserved-communities
https://www.sophiagenetics.com/en_US/news/media-mix/details/news/sophia-genetics-raises-110-million-in-oversubscribed-new-funding-round.html

 Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast

Another Alzheimer’s failure, COVID19 updates, two stories in the supplements space, and Taysha goes public.

Sponsors

https://www.thescopemethod.com

Story References

https://ir.acimmune.com/news-releases/news-release-details/ac-immune-reports-top-line-results-tauriel-phase-2-trial

https://www.medrxiv.org/content/10.1101/2020.09.23.20199604v1.full.pdf

https://www.cell.com/cell-metabolism/fulltext/S1550-4131(20)30417-4

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0239799

https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-pricing-initial-public-offering

Music by Luke Goodson

https://www.soundcloud.com/lukegoodson

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast

Finch does probiotics the expensive way, lipid nanoparticles, a followup on transparency, and LAVA gains immuno-therapy support.



Sponsors
https://www.thescopemethod.com

Story References
https://www.businesswire.com/news/home/20200916005915/en/Moderna-and-Vertex-Establish-New-Collaboration-to-Treat-Cystic-Fibrosis-Using-Gene-Editing

https://finchtherapeutics.com/blog/finch-therapeutics-announces-90-million-financing

https://www.modernatx.com/sites/default/files/mRNA-1273-P301-Protocol.pdf

https://www.businesswire.com/news/home/20200916005913/en/LAVA-Therapeutics-Announces-83-million-Series-C-Financing-to-Advance-Novel-Immuno-Oncology-Programs

Music by Luke Goodson

https://www.soundcloud.com/lukegoodson

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast

This week, vaccines and shark statistics, are noses the ultimate pipedream, and eye drops to replace eye-glasses.




Sponsors

https://www.thescopemethod.com

Story References

https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/statement-on-astrazeneca-oxford-sars-cov-2-vaccine-azd1222-covid-19-vaccine-trials-temporary-pause.html

https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/covid-19-vaccine-azd1222-clinical-trials-resumed-in-the-uk.html

https://www.globenewswire.com/news-release/2020/09/10/2091685/0/en/Satsuma-Pharmaceuticals-Announces-Topline-Results-from-EMERGE-Phase-3-Trial-of-STS101-for-the-Acute-Treatment-of-Migraine.html

https://www.orasis-pharma.com/orasis-raises-30-million-to-advance-the-clinical-development-of-novel-treatment-for-presbyopia/

Music by Luke Goodson

https://www.soundcloud.com/lukegoodson

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast

Roche earns FDA approval for a combined flu/COVID diagnostic, I-Mab signs with Abbvie for $2 billion, PPD partners to treat lupus, and BioNTech/Pfizer add more COVID candidates while Moderna adds bad press.



Sponsors
www.thescopemethod.com

Story References
https://www.businesswire.com/news/home/20200903005517/en/PPD-Lupus-Therapeutics-Collaborate-Support-Lupus-Clinical
https://www.fiercebiotech.com/biotech/pfizer-biontech-quietly-usher-a-5th-covid-19-jab-into-clinic-analyst
https://www.npr.org/2020/09/04/908305074/bad-optics-or-something-more-moderna-executives-stock-sales-raise-concerns
https://www.roche.com/media/releases/med-cor-2020-09-04.htm
https://www.usnews.com/news/us/articles/2020-09-02/us-nih-awards-nine-companies-129-million-to-scale-up-covid-19-testing

Music by Luke Goodson
www.soundcloud.com/lukegoodson

 
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

This week, we take a break from our normal news cycle to focus on one big idea; healthcare is politics. But first, a quick update.


Sponsors
www.thescopemethod.com

Story References
https://www.sec.gov/Archives/edgar/data/1620463/000156459020041369/atha-s1.htm

Music by Luke Goodson
www.soundcloud.com/lukegoodson

 
The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.

Originally Published as The Niche Podcast

Johnson & Johnson acquires Momenta, the White House and FDA disagree, and the emergence of decentralized clinical trial management.

Sponsors
www.thescopemethod.com

Story References
https://www.momentapharma.com/investors-and-news/press-releases/press-releases-details/2020/Momenta-Enters-Definitive-Agreement-with-Johnson--Johnson/
https://www.hhs.gov/coronavirus/testing/recission-guidances-informal-issuances-premarket-review-lab-tests/index.html
http://www.science37.com/solutions/

Music by Luke Goodson
www.soundcloud.com/lukegoodson

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast

Samsung Biologics builds big, Modern (again), microparticles for timed-release chemotherapy, and Qiagen says ‘no’ to acquisitions.


Sponsors
www.thescopemethod.com

Story References
https://samsungbiologics.com/front/en/mediaCenter/pressReleasesView.do?boardSeq=781&schBoardCtgryCcd=&schString=&schBoardYear=&boardDtm=1597071600000&page=1#
https://investors.modernatx.com/news-releases
https://stm.sciencemag.org/content/12/556/eaaz6606
https://www.fiercebiotech.com/medtech/thermo-fisher-s-12-5b-deal-for-qiagen-flops-as-covid-19-test-demand-lights-new-path-forward

Music by Luke Goodson
www.soundcloud.com/lukegoodson

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast

Biogen and Denali partner for Parkinson’s, the US pushes American-based drug manufacturing, and the secret to Parasitic Sexual Partners uncovered.

Sponsors
www.thescopemethod.com

Story References
https://investors.biogen.com/news-releases/news-release-details/biogen-and-denali-collaborate-lrrk2-program-parkinsons-disease
https://science.sciencemag.org/content/early/2020/07/29/science.aaz9445
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832911/
https://www.whitehouse.gov/presidential-actions/executive-order-ensuring-essential-medicines-medical-countermeasures-critical-inputs-made-united-states/

Music by Luke Goodson
www.soundcloud.com/lukegoodson

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast

We review a few of the big winners from operation warp speed, Merck continues to be quietly successful, and a new CAR T treatment, Tecartus, gets FDA approval.

Sponsors
www.thescopemethod.com

Story References
https://s21.q4cdn.com/488056881/files/doc_financials/2020/q2/Merck-2Q20-Earnings-News-Release.pdf
https://www.gilead.com/news-and-press/press-room/press-releases/2020/7/us-fda-approves-kites-tecartus-the-first-and-only-car-t-treatment-for-relapsed-or-refractory-mantle-cell-lymphoma
https://www.hhs.gov/about/news/index.html

Music by Luke Goodson
www.soundcloud.com/lukegoodson

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.